Today, continuous glucose monitoring systems (CGM) are being actively incorporated into public and compulsory health insurance programs in many countries around the world, which indicates official recognition of the technology as a standard of care.
For manufacturers, this provides access to a sustainable and predictable market, while for patients, it eliminates the primary obstacle: the high cost of a vital medical device.
Countries with CGM included in public health insurance:
Europe ranks first in coverage. In France, CGM is fully reimbursed for patients with type 1 diabetes and insulin-dependent type 2 diabetes. In Germany, reimbursement is available to all insulin users. The United Kingdom offers CGM coverage to all patients diagnosed with type 1 diabetes. Reimbursement programs are also in place in Eastern Europe, spanning from Croatia to Poland.
North America: In the US, up to 80% of CGM costs are reimbursed for patients using insulin. In Canada, reimbursement is available in several provinces.
Asia: In Japan, CGM is fully covered by state insurance, while in South Korea, it is covered partially.
The global trend toward expanding reimbursement programs for continuous glucose monitoring (CGM) systems opens up strategic opportunities for MLC to enter key international markets. Securing the CE marking will enable the company to introduce its products to the European market and establish the essential groundwork for future submissions to public reimbursement programs in countries where CGM is already embedded in the healthcare system.
Once the technology is incorporated into the public health insurance system, it is no longer a costly alternative but rather an affordable standard of care.
MLC is committed to moving in this direction. Thank you for being with us on this journey.
